Lorenzo Gallon1, Opas Traitanon, Yuming Yu, Bo Shi, Joseph R Leventhal, Joshua Miller, Valeria Mas, Xu L, James M Mathew. 1. 1 Department of Medicine-Nephrology, Northwestern University Feinberg School of Medicine, Chicago, IL. 2 Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, IL. 3 Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL. 4 Department of Medicine and Rheumatology Division, Northwestern University Feinberg School of Medicine, Chicago, IL. 5 Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL. 6 Department of Surgery, University of Virginia, Charlottesville, VA.
Abstract
BACKGROUND: Previously, we had reported the role of tacrolimus (TAC) versus sirolimus (SRL) on the generation of regulatory T cells (Tregs) in primary MLR assays with SRL, demonstrating a uniquely supportive effect. However, the mechanisms associated with their actions on alloreactive human T cells are not fully understood. Therefore, we tested whether TAC and SRL differentially affect already alloactivated human CD4 T-cell subsets. METHODS: Alloreactive CD4CD45RA/CD45RO T cells generated in 9-day MLR were cocultured with anti-CD3 and autologous antigen presenting cells plus interleukin (IL)-2 in presence of TAC, SRL, or both, and the Tregs generated after another 5 to 6 days were phenotypically, molecularly, and functionally characterized. RESULTS: Tacrolimus significantly and SRL modestly inhibited interferon (IFN)-γ (Th1) and IL-17 (Th17)-producing cells. At clinical therapeutic concentrations, SRL, however, significantly increased forkhead/winged helix transcription factor P3 (FOXP3) Tregs, whereas TAC inhibited this T-cell population dose dependently and significantly. When used in combination, TAC and SRL had additive effects on inhibition of IFN-γ- and IL-17-producing cells. This was in contrast to the ability of SRL to reverse TAC-mediated inhibition of FOXP3-expressing cells. Proinflammatory cytokines (IL-1β, IL-6, and tumor necrosis factor-α) added to cultures caused significant decrease in FOXP3 Tregs that was again reversed by SRL. Sirolimus-derived Tregs were phenotypically normal, anergic to allostimulation, and suppressed proliferation of allogeneic effector T-cells. CONCLUSIONS: Thus, although TAC inhibits all alloreactive T cells, SRL promotes the differentiation and expansion of donor-specific Tregs without secondary reprogramming to IFN-γFOXP3 and IL-17FOXP3 Treg subsets. These results, although performed in an artificial in vitro model, add clinically applicable information on how these agents affect T-cell subpopulations.
BACKGROUND: Previously, we had reported the role of tacrolimus (TAC) versus sirolimus (SRL) on the generation of regulatory T cells (Tregs) in primary MLR assays with SRL, demonstrating a uniquely supportive effect. However, the mechanisms associated with their actions on alloreactive human T cells are not fully understood. Therefore, we tested whether TAC and SRL differentially affect already alloactivated human CD4 T-cell subsets. METHODS: Alloreactive CD4CD45RA/CD45RO T cells generated in 9-day MLR were cocultured with anti-CD3 and autologous antigen presenting cells plus interleukin (IL)-2 in presence of TAC, SRL, or both, and the Tregs generated after another 5 to 6 days were phenotypically, molecularly, and functionally characterized. RESULTS:Tacrolimus significantly and SRL modestly inhibited interferon (IFN)-γ (Th1) and IL-17 (Th17)-producing cells. At clinical therapeutic concentrations, SRL, however, significantly increased forkhead/winged helix transcription factor P3 (FOXP3) Tregs, whereas TAC inhibited this T-cell population dose dependently and significantly. When used in combination, TAC and SRL had additive effects on inhibition of IFN-γ- and IL-17-producing cells. This was in contrast to the ability of SRL to reverse TAC-mediated inhibition of FOXP3-expressing cells. Proinflammatory cytokines (IL-1β, IL-6, and tumor necrosis factor-α) added to cultures caused significant decrease in FOXP3 Tregs that was again reversed by SRL. Sirolimus-derived Tregs were phenotypically normal, anergic to allostimulation, and suppressed proliferation of allogeneic effector T-cells. CONCLUSIONS: Thus, although TAC inhibits all alloreactive T cells, SRL promotes the differentiation and expansion of donor-specific Tregs without secondary reprogramming to IFN-γFOXP3 and IL-17FOXP3 Treg subsets. These results, although performed in an artificial in vitro model, add clinically applicable information on how these agents affect T-cell subpopulations.
Authors: Christian Morath; Anita Schmitt; Martin Zeier; Michael Schmitt; Flavius Sandra-Petrescu; Gerhard Opelz; Peter Terness; Matthias Schaier; Christian Kleist Journal: Langenbecks Arch Surg Date: 2015-06-17 Impact factor: 3.445
Authors: Christian Morath; Anita Schmitt; Florian Kälble; Martin Zeier; Michael Schmitt; Flavius Sandra-Petrescu; Gerhard Opelz; Peter Terness; Matthias Schaier; Christian Kleist Journal: Pediatr Nephrol Date: 2017-02-23 Impact factor: 3.714
Authors: David Merino; David San Segundo; Juan M Medina; Emilio Rodrigo; Esther Asensio; Juan Irure; Gema Fernández-Fresnedo; Manuel A Arias; Marcos López-Hoyos Journal: Immunology Date: 2016-03-29 Impact factor: 7.397
Authors: Yingkai Li; Jeffrey T Guptill; Melissa A Russo; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; James F Howard; Manisha Chopra; Weibin Liu; John S Yi Journal: Exp Neurol Date: 2018-11-22 Impact factor: 5.330
Authors: Cyd M Castro-Rojas; Alzbeta Godarova; Tiffany Shi; Sarah A Hummel; Adele Shields; Simon Tremblay; Rita R Alloway; Michael B Jordan; E Steve Woodle; David A Hildeman Journal: Transplantation Date: 2020-05 Impact factor: 4.939